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n Patients With Stable Angina
Double-Blind, Placebo-Controlled, Phase 2 Trial
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illiam B. Smith, MD, FACC,§ Steven G. Chrysant, MD, PHD, FACC,
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or the Fasudil Study Group
elbourne, Florida; St. Louis, Missouri; Montville, New Jersey; New Orleans, Louisiana;
klahoma City, Oklahoma; Santa Ana, California; Madison, Wisconsin; and Auburn, Maine
OBJECTIVES This study sought to evaluate the efficacy and safety of fasudil, an orally available rho kinase
inhibitor, in patients with stable angina.
BACKGROUND Several small, non–placebo-controlled trials suggest that fasudil reduces myocardial ischemia
in patients with stable or vasospastic angina.
METHODS In a multicenter, double-blind, placebo-controlled, randomized trial, the efficacy and safety of
fasudil were evaluated in stable angina patients. Of the 206 patients screened, 84 patients with
reproducible exercise times were randomized 1:1 to fasudil or placebo. Nitroglycerin as
needed and a beta- or calcium-channel blocker were allowed. Fasudil or matching placebo was
force-titrated from 20 mg three times daily to 80 mg twice daily with 20 mg twice-daily
increments every two weeks. Symptom-limited exercise testing was performed after two, four,
six, and eight weeks of treatment.
RESULTS At peak, exercise duration was significantly improved at all visits in both groups, although
exercise duration was numerically greater in patients receiving fasudil versus those receiving
placebo. Time to1 mm ST-segment depression was increased with fasudil at both peak and
trough compared with placebo (172.1 s vs. 44.0 s, p  0.001, and 92.8 s vs. 26.4 s, p  0.02,
respectively). Fasudil improved Seattle Angina Questionnaire scores. No significant differ-
ences in Canadian Cardiovascular Society class, time to angina, or frequency of angina or
nitroglycerin use were noted between groups. Fasudil did not affect heart rate or blood
pressure, and was well tolerated.
CONCLUSIONS Fasudil up to 80 mg three times daily significantly increased the ischemic threshold of angina
patients during exercise with a trend toward increased exercise duration. Further investigation
of fasudil doses 80 mg three times daily is indicated. (J Am Coll Cardiol 2005;46:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.07.0471803–11) © 2005 by the American College of Cardiology Foundation
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hhronic stable angina, stimulated by emotional or physical
tress, is the initial symptom in about 50% of patients with
schemic heart disease (1). Current treatment options in-
lude lifestyle management, pharmacotherapy to reduce myo-
ardial oxygen demand and/or to increase myocardial blood
ow, surgical or percutaneous revascularization procedures,
nd several alternative procedures, including transmyocardial
evascularization and enhanced external counterpulsation (1–
). However, many patients remain symptomatic while receiv-
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ardiology Associates, Auburn, Maine; ††VA Medical Center, University of Okla-
oma Health Science Center, Oklahoma City, Oklahoma. Supported by Berlex
aboratories Inc. Drs. Keefe and Morales-Ballejo are employees of and own stock in
erlex Laboratories Inc. Drs. Vicari, Chaitman, Smith, Chrysant, Tonkon, Weiss,
nd Bittar have received research grants from Berlex Laboratories Inc.a
Manuscript received April 8, 2005; revised manuscript received May 25, 2005,
ccepted July 11, 2005.ng drug therapy or despite revascularization procedures. Thus,
dditional therapeutic options are needed.
Rho kinase, an intracellular signaling molecule involved
n the vascular smooth muscle contractile response to
gonists such as acetylcholine, angiotensin II, endothelin,
orepinephrine, platelet-derived growth factor, and serotonin
4–6), has been proposed as a therapeutic target for treating
table angina. In smooth muscle cells, contraction is stimu-
ated by G-protein–coupled receptors, which activate Rho,
hich subsequently activates Rho kinase (7). Rho kinase
hosphorylates and inactivates myosin regulatory light chain
MRLC) phosphatase. In the absence of a functional
RLC phosphatase, MRLC remains in the active (phos-
horylated) form, and interaction between actin and myosin
esults in sustained contraction. Animal models of coro-
ary artery spasm have shown that Rho kinase inhibitors
ffectively suppress vasoconstriction (8,9). Similar results
ave been obtained during in vivo studies of human
rteries (10).
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Fasudil in Patients With Stable Angina November 15, 2005:1803–11An intravenous formulation of fasudil, a selective Rho
inase inhibitor (11), is approved in Japan to prevent cerebral
asospasm after subarachnoid hemorrhage (12) and has been
onsidered for treatment of angina. Several phase 1 studies
ere conducted in patients with vasospastic angina (either
ngiographically detectable or microvascular) who devel-
ped electrocardiographic evidence of ischemia in response
o acetylcholine. The results showed that acetylcholine-
timulated ischemia was prevented in 85% of patients by
15-min intracoronary infusion of 4.5 mg fasudil (13,14).
Fasudil is bioavailable after oral administration (15) and
as a half-life of 5.5  0.87 h in tablet form (16). In phase
dose-finding trials conducted in Japanese patients with
table effort angina, fasudil monotherapy at doses ranging
rom 5 mg three times daily to 40 mg three times daily
ncreased maximum exercise time and time to the onset of
1 mm ST-segment depression compared with baseline.
asudil was well tolerated, with minimal effects on blood
ressure or heart rate at rest or during exercise (15).
owever, these trials were not placebo-controlled, and use
f concomitant cardiovascular drugs was not reported.
urthermore, the Japanese patient population studied has an
ncreased tendency toward vasospasm (15).
This phase 2, placebo-controlled, dose-escalation study
as designed to evaluate the efficacy and safety of fasudil at
oses up to 80 mg three times daily in American patients
ith stable angina already receiving standard medical ther-
py for cardiovascular disease.
ETHODS
atients. Male and female patients (ages 30 to 80 years)
ith evidence of coronary artery disease and stable angina
Canadian Cardiovascular Society [CCS] grading [17] class
or 3) for at least eight weeks were enrolled in the study.
atients with unstable angina or with angina of CCS class
or 4 were excluded from the study. Patients able to
xercise for 3 min or for 10 min in the qualifying
xercise treadmill testing (ETT) during the run-in period
12 min in the final qualifying ETT) or with variability in
xercise time of more than 15% were also excluded.
dditional exclusion criteria included patients with un-
reated life-threatening ventricular arrhythmias, those with
nderlying disease other than coronary artery disease result-
ng in a life expectancy of 12 months, patients with a
yocardial infarction or those undergoing coronary artery
ypass surgery in the previous 3 months, patients with
Abbreviations and Acronyms
CCS  Canadian Cardiovascular Society
ECG  electrocardiogram
ETT  exercise treadmill testing
MRLC  myosin regulatory light chain
SAQ  Seattle Angina Questionnairengioplasty in the previous 6 (without stent) or 12 (with stent) ponths, and patients who received transmyocardial laser
evascularization within the previous 3 months or enhanced
xternal counterpulsation in the previous 12 months.
tudy design. This was a multicenter, double-blind,
lacebo-controlled, forced-titration, parallel group study,
omprising a three-week run-in period and an eight-week
ouble-blind treatment period. During treatment, patients
ere randomized to receive either fasudil (20 mg three times
aily, escalating in 20-mg increments at two-week intervals
o 80 mg three times daily) or matching placebo in a 1:1
atio (Fig. 1).
FFICACY END POINTS. The primary efficacy end point was
he change from baseline in total ETT duration at peak after
wo, four, six, and eight weeks of treatment. Secondary
fficacy end points were changes from baseline in total ETT
uration at trough and at four hours after dosing and the
hange from baseline in time to 1-mm ST-segment
epression at peak after two, four, six, and eight weeks of
reatment.
Tertiary efficacy end points were assessed after two, four,
ix, and eight weeks of treatment as well. These included
hanges from baseline in time to 1-mm ST-segment
epression at trough and four hours after dosing, time of
nset of angina, 1 class reduction in CCS angina class,
ngina attack frequency, weekly sublingual nitroglycerin
onsumption, and scales of the Seattle Angina Question-
aire (SAQ) (18).
AFETY END POINTS. All safety variables (adverse events,
aboratory abnormalities, vital signs, and electrocardiogram
ECG]) were assessed at baseline and at subsequent visits.
dditional visits at weeks 5 and 7 were scheduled for
valuation of safety data when laboratory test data and any
ignificant adverse events were assessed. A central laboratory
Covance Laboratories Inc., Indianapolis, Indiana) analyzed
linical laboratory samples.
xperimental phases. RUN-IN PERIOD. During the run-in
igure 1. Schematic diagram of the study design. Exercise testing (X) was
erformed before dosing (trough), 1 h after dosing (peak), and 4 h after
osing of both fasudil and matching placebo tablets. tid  three times
aily.eriod, long-acting nitrates were discontinued, and patients
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November 15, 2005:1803–11 Fasudil in Patients With Stable Anginanderwent a one-week washout of anti-anginal drugs ex-
luding sub-lingual nitroglycerin and one anti-anginal med-
cation (beta-blocker or calcium-channel blocker). This was
ollowed by a two-week single-blind, placebo run-in period
o obtain baseline ETT data.
During the single-blind run-in phase, patients performed
p to three qualifying ETTs according to a modified Balke
rotocol (Appendix), showing exercise-induced ST-
egment depression 1 mm compared with baseline asso-
iated with grade 3 or 4 angina. The first ETT was to show
n ability to exercise for at least 3 min but no more than 10
in before stopping because of angina of moderate severity
grade 3 or 4 angina). A subsequent ETT was performed
ithin three to five days of the first, with the difference in
xercise duration expected to decrease within 15% of the
rst ETT. In patients not achieving this target, a third ETT
ould be performed. Patients achieving a difference in
xercise duration within 15% of the second ETT with
xercise duration 12 min were included in the study. In
ddition, an ST-segment depression of 1 mm associated
ith grade 3 or 4 angina was required in each ETT. Patients
ho qualified for inclusion in the study received one dose of
ingle-blind placebo medication, and symptom-limited ex-
rcise tests were repeated at one and four hours after dosing.
he ETT data were obtained at each time point and,
ogether with the last qualifying ETT, were used as the
aseline ETTs.
REATMENT PERIOD. The run-in period was followed by
n eight-week double-blind period with administration of
ncreasing doses of fasudil or placebo (Fig. 1). During the
ouble-blind treatment phase, ETT was repeated before
trough) and 1 h (peak) and 4 h after dosing at day 1, and
fter 2, 4, 6, and 8 weeks of treatment. A 12-lead ECG and
ital sign measurements in both supine and standing posi-
ions were taken before each ETT at baseline and after two,
our, six, and eight weeks of treatment. An ECG was
ecorded every 30 s during exercise, and blood pressure was
ecorded during the final 30 s of exercise. The ST-segment
epressions were measured manually. All rest and exercise
CG data were analyzed by the St. Louis University Core
aboratory, St. Louis, Missouri.
THICAL CONSIDERATIONS. An independent ethics com-
ittee, institutional review board, or research ethics board
pproved the study protocol at each of the 33 participating
tudy centers. All protocol amendments were subjected to
he same approval process. The study was conducted in
ccordance with the ethical principles laid out in the
eclaration of Helsinki, the Food and Drug Administration
ode of Federal Regulations, and the International Con-
erence of Harmonization–Good Clinical Practice guide-
ines. All patients gave written informed consent to their
articipation in the study.
tatistical analysis. Based on an expected detectable dif-
erence of 45 sec (0.75 min) between treatment and placebo
roups in change from baseline in peak exercise duration, dhe sample size was estimated at 40 patients per treatment
roup. This provided an 85% statistical power to detect the
ifference, at the alpha  0.05 significance level, based on a
wo-tailed t test with an assumed standard deviation of 1.1
in.
One-way analysis of variance (equivalent to a t test when
wo groups are compared) was used to analyze the primary,
econdary, and tertiary efficacy variables in the efficacy-
valuable set. The exceptions to this were time to 1 mm
T-segment depression (log rank test) and change in CCS
ngina class (Fisher exact test).
ESULTS
atients’ baseline characteristics. A total of 206 patients
ere screened for entry into the study. Of these, 122
atients were excluded, primarily because of failure to meet
ntry criteria (Fig. 2). The 84 patients randomized to
reatment (41 in the fasudil group and 43 in the placebo
roup) all received at least one dose of study medication.
here were no statistical differences in baseline characteris-
ics in the two treatment groups (Table 1). Patients entered
nto the study were receiving a stable dose of one antianginal
edication (Table 2). The majority (65%) received beta-
lockers during the double-blind phase, whereas 54% used
hort-acting nitrates for the relief of acute anginal attacks.
All patients who received at least one dose of study
edication and had a follow-up evaluation were included in
he efficacy analysis set. All 84 patients randomized to
reatment were included in this data set. A total of nine
atients (five in the fasudil group, four in the placebo group)
iscontinued the study prematurely, primarily because of
dverse events (Fig. 2).
fficacy end points. PRIMARY EFFICACY VARIABLE:
READMILL EXERCISE DURATION AT PEAK. At peak, the
hange in ETT duration compared with baseline was
ignificantly improved at all visits in both the fasudil and
lacebo groups. There was a numerically greater but not
tatistically significant increase in ETT duration at peak in
atients receiving fasudil compared with those receiving
lacebo after two, four, six, and eight weeks of treatment
Fig. 3). At eight weeks (80 mg three times daily), the
ncrease in time to exercise cessation was 118.4 131.6 s in
atients given fasudil compared with 86.1  142.2 s in
atients given placebo (p 0.311). Improvement seemed to
e dose- and/or time-dependent.
ECONDARY EFFICACY VARIABLES. At peak, both the pla-
ebo and fasudil treatment groups showed significant
ithin-group improvements from baseline in the mean time
o 1 mm ST-segment depression. In the fasudil group,
ignificant improvements were seen at all visits (week 2, p
.005; weeks 4, 6, and 8, p 0.001), whereas in the placebo
roup, significant improvements were observed at weeks 2,
, and 6 (p  0.027, 0.007, and 0.004, respectively). The
ean change from baseline in time to 1 mm ST-segment
epression (myocardial ischemia) at peak was greater in the
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Fasudil in Patients With Stable Angina November 15, 2005:1803–11asudil-treated group compared with the placebo group at
eeks 2, 4, 6, and 8 (Fig. 4). This difference reached
tatistical significance at eight weeks (80 mg three times
aily), when the time to myocardial ischemia was 172.1 
24.5 s for patients given fasudil compared with 44.0 
09.6 s in the placebo group (p  0.001).
There were no consistent numerical differences in ETT
uration, either at trough or at four hours after dosing,
etween fasudil and placebo after two, four, six, or eight
eeks of treatment.
ERTIARY END POINTS. At trough, the mean time to 1
m ST-segment depression was significantly increased to
2.8 s with 80-mg three-times-daily fasudil (week eight)
ersus 26.4 s with placebo treatment (p  0.02). There was
lso a statistically significant treatment effect for time to 1
m ST-segment depression (p  0.006) as assessed by the
og-rank test. However, no significant differences between
reatment groups were observed at four hours after dosing.
Fasudil had little effect on several additional parameters
f efficacy. No significant changes in the time to onset of
ngina, weekly frequency of angina, or use of nitroglycerin
ere noted. A dose- and time-related trend in the percent-
ge of patients with 1 CCS class improvement was
bserved, although the differences between the placebo and
asudil groups did not reach significance (Fig. 5).
Nevertheless, fasudil improved measures of quality of life.
he SAQ physical limitation scale for patients receiving
asudil was improved at all visits, whereas the scores for
lacebo patients worsened. The differences in SAQ score
etween patients receiving fasudil and those receiving pla-
ebo were significant at the 60- and 80-mg three-times daily
asudil doses (Fig. 6A). The SAQ treatment satisfaction
Figure 2. Patient discores (Fig. 6B) also improved with fasudil treatment, with estatistically significant difference between patients receiv-
ng fasudil and those receiving placebo observed at the 40-
nd 60-mg three-times-daily doses.
afety. Fasudil was well tolerated at a dose of 20 to 80 mg
hree times daily. A total of 49 patients (58%) reported
dverse events during the double-blind treatment period.
he incidence of adverse events was similar in the two
reatment groups, with 23 of 43 patients (53%) in the
lacebo group and 26 of 41 patients (63%) in the fasudil
roup reporting adverse events. Because only one or two
atients experienced any given syndrome and none of the
ifferences were statistically significant, these disorders are
escribed by organ system. The body systems apparently
ore frequently affected in the fasudil group than in the
lacebo group included the skin and subcutaneous tissue,
nd the vascular system (Table 3). Skin disorders in patients
reated with fasudil were heterogeneous, including allergic
ermatitis, a bruise, diaphoresis, facial erythema, erythro-
apular rash, erythematous rash, hives, and keratosis. Sim-
larly, vascular disorders in patients receiving fasudil were
eterogeneous, including facial flushing, ecchymoses, hypo-
ension, hypertension, and a Raynaud-like phenomenon.
The majority of the adverse events reported were classi-
ed as mild to moderate. There were no deaths during the
tudy. Two patients (5%) in the placebo group and five
atients (12%) in the fasudil group reported severe adverse
vents. In the placebo group, the severe events were myo-
ardial infarction, unstable angina, and upper gastrointesti-
al hemorrhage. In the fasudil group, the severe events were
orsened chronic stable angina pectoris, chest pain, in-
reased ocular pressure, headache, hives, and hypertension.
The proportion of patients with adverse events consid-
on during the study.red to be related to study medication in the opinion of the
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November 15, 2005:1803–11 Fasudil in Patients With Stable Anginanvestigator was higher in the placebo group (30% [13 of 43]
s. 22% [9 of 41] in the fasudil group).
No dose- or time-dependent trends in adverse events
ere observed between the 20- and 60-mg three-times-
aily fasudil groups. At these doses, no difference in the
ncidence of adverse events between fasudil and placebo
roups was observed. Although slightly more patients re-
orted adverse events at the 80-mg three-times-daily fasudil
ose, there was no significant difference compared with the
lacebo group.
Within-group changes from baseline were observed for
ome laboratory parameters. Both aspartate transferase and
lanine transferase were decreased in both treatment groups,
Table 1. Patient Baseline Characteristics
Variable
Age (yrs)
Mean (SD)
Min-max
65, n (%)
Gender
Male, n (%)
CCS angina class
2, n (%)
3, n (%)
Weekly number of anginal attacks
n
Mean (SD)
Min-max
Weekly nitroglycerin tablet use
n
Mean (SD)
Min-max
Exercise duration at peak
n
Mean (SD)
Min-max
Time to 1 mm ST-segment depression at peak (s)
n
Mean (SD)
Min-max
Disease perception/quality of life score†
n
Mean (SD)
Min-max
Heart rate (beats/min)
n
Resting supine, mean (SD)
Peak exercise, mean (SD)
Systolic blood pressure (mm Hg)
n
Resting supine, mean (SD)
Peak exercise, mean (SD)
Diastolic blood pressure (mm Hg)
n
Resting supine, mean (SD)
At peak exercise, mean (SD)
*Treatment effect p values for continuous data were obtained
as a factor. Treatment effect p values for categorical data we
the modified Seattle Angina Questionnaire.
CCS  Canadian Cardiovascular Society; SD  standarPlacebo
(n  43)
Fasudil
(n  41)
p
Value*
0.435
64.4 (9.62) 66.0 (9.42)
49–80 44–82
21 (49) 18 (44) 0.668
1.000
32 (74) 31 (76)
0.738
3 (91) 37 (90)
4 (9) 4 (10)
0.167
38 39
2.4 (3.84) 4.3 (7.37)
0–16 0–34
0.115
38 39
0.5 (1.67) 2.2 (6.26)
0–10 0–33
0.374
43 41
443.7 (144.20) 470.0 (123.17)
176–690 228–690
0.107
34 36
333.1 (116.39) 382.4 (142.81)
150–540 90–660
0.364
42 40
66.3 (19.65) 63.0 (24.26)
25–100 8–100
NS
39 39
68.4 (14.34) 67.9 (12.03)
114.1 (18.56) 118.2 (17.86)
NS
39 39
137.5 (22.59) 137.5 (15.48)
171.8 (22.94) 167.8 (19.73)
NS
39 39
79.9 (9.34) 79.3 (8.61)
84.4 (14.57) 85.0 (13.83)
from a one-way analysis of variance model with treatment group
re obtained from the Fisher Exact probability test. †Derived fromnd platelet count was decreased in the placebo group and gable 2. Concomitant Medication Used During Double-Blind
reatment Phase
oncomitant Medication
Placebo
(n  43)
Fasudil
(n  41)
itrates 20 (47) 25 (61)
eta-blockers 30 (70) 25 (61)
alcium channel blockers 9 (21) 8 (20)
CE inhibitors 16 (37) 14 (34)
ngiotensin receptor blockers 7 (16) 8 (20)
iuretics 11 (26) 12 (29)
MG-CoA inhibitors 32 (74) 28 (68)
ntiplatelet agents 35 (81) 35 (85)
rugs for diabetes 7 (16) 5 (12)
alues are n (%).
ACE  angiotensin-converting enzyme; HMG CoA  3-hydroxy-3-methyl-
lutaryl coenzyme A (reductase).
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Fasudil in Patients With Stable Angina November 15, 2005:1803–11ncreased in the fasudil group but with no significant
ifference between treatment groups. A statistically signifi-
ant but not clinically significant increase in serum creati-
ine was observed in the fasudil group (from 1.02 to 1.08
g/dl, p  0.05) but not in the placebo group (1.03 to 1.01
g/dl, p  0.05). The mean changes from baseline for the
ther laboratory parameters were minimal, with no observ-
ble within-group or between-group trends.
There were few statistically significant differences be-
ween the effects of fasudil and placebo on heart rate, blood
ressure, or the product of heart rate and systolic blood
ressure at any time point, and there was no evidence of
ither treatment-related or dose-dependent effects during
xercise at peak (Table 4). Similarly, few changes in 12-lead
CG findings were noted during the study. No change in
igure 3. Changes in exercise treadmill testing duration from baseline at
eak for fasudil- (solid bars) and placebo-treated (open bars) patients
mean  standard deviation). tid  three times daily.
igure 4. Changes in mean time to 1 mm ST-segment depression froma
aseline for fasudil- (solid bars) and placebo-treated (open bars) patients.
p  0.001. tid  three times daily.T or QTc Fridericia from baseline were found at any time
fter dosing.
ISCUSSION
his phase 2 dose-finding trial in patients with stable
ngina showed that titrating fasudil to 80 mg three times
aily over eight weeks improved exercise time compared
ith baseline, with a statistical trend toward improvement
ompared with placebo. A significant, nearly four-fold
ncrease in mean time to 1 mm ST-segment depression
myocardial ischemia) compared with placebo was observed
t peak (1 h after dosing) with a fasudil dose of 80 mg three
imes daily. Lesser effects of fasudil on myocardial ischemia
ere observed four hours after dosing and at trough.
dministration of fasudil was associated with significant
mprovements in SAQ physical limitation and treatment
atisfaction scores compared with placebo. A favorable trend
n CCS class was also shown. No differences in time to
nset of angina, weekly frequency of angina, or use of
itroglycerin were noted between the treatment groups. The
ates of adverse events and withdrawal because of adverse
vents were similar in both treatment groups. Most adverse
vents were mild and not considered related to study
edication.
Although the primary end point was not achieved, the
esults obtained in this study are promising. In retrospect,
he study was underpowered to detect an increase in exercise
ime with fasudil therapy. In the power calculation, the
agnitude of the anticipated effect was overestimated (0.75
in vs. an actual difference of 0.5 min) and the standard
eviation of patient exercise times was underestimated (1.1
in vs. 1.98 min in the fasudil group and 2.37 min in the
lacebo group). Thus, a larger study (approximately 300 per
roup) is required to determine whether fasudil therapy is
igure 5. Improvements in angina by1 Canadian Cardiovascular Society
ngina class in patients treated with fasudil (solid bars) and placebo (open
ars). tid  three times daily.ssociated with improved exercise time.
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November 15, 2005:1803–11 Fasudil in Patients With Stable AnginaHowever, the study was appropriately powered to detect
ifferences in time to 1 mm ST-segment depression, the
econdary end point. This measurement is more reproduc-
ble than exercise testing, and changes in this parameter are
lacebo-independent and associated with a poor prognosis
19). Furthermore, the magnitude of the effects of fasudil on
1 mm ST-segment elevation are comparable to the
agnitude of changes observed in separate studies of the
eta-blocker propranolol and nine calcium-channel blockers
ompared with placebo (20). These established therapies for
ngina increased the time to myocardial ischemia by 1.4 to
.7 min (20). The 2.1-min improvement observed with
asudil is within this range and was achieved despite
oncomitant use of background medication. In contrast,
anolazine, a partial fatty acid oxidation inhibitor in devel-
pment for stable angina, increased the time to myocardial
schemia at peak compared with placebo by 55.6  8.2 s
mean  standard error) as monotherapy (1,000 mg twice
aily) and by 34.5  11.9 s when given in addition to
igure 6. Improvement in Seattle Angina Questionnaire score. (A) Phys-
cal limitation scale. (B) Treatment satisfaction scale. *p  0.05. tid 
hree times daily. Open bars  placebo; solid bars  fasudil.tenolol, amlodipine, or diltiazem (21,22). iThe results of this study seem to differ from the results of
he previous phase 2 trials with fasudil (15). For example,
ore end points improved significantly in the previous
rials, including maximum exercise time, the number of
ngina attacks per week and use of sublingual nitroglycerin.
owever, these studies were not placebo-controlled. Signif-
cance in the previous study was compared with baseline,
hereas significance in this trial was determined compared
ith placebo. When the results of this trial are compared
ith baseline, maximum exercise time, the frequencies of
ngina attacks, and nitroglycerin use significantly increased
n both the placebo and fasudil treatment groups. Thus,
hese results are similar to those of the previous study and
mphasize the importance of comparison of active therapy
o a placebo.
Other differences in the results between this and previous
rials may be meaningful. Whereas no dose-response rela-
ionship in time to myocardial ischemia was observed with
asudil doses of 5 mg three times daily to 40 mg three times
aily (15), an apparent dose-dependent trend was observed
n this trial with doses ranging from 20 mg three times daily
o 80 mg three times daily. The magnitude of the increase
n time to 1 mm ST-segment depression at 80 mg three
imes daily in this study was 172 s (2.87 min), compared
ith 109 s (1.8 min) at 40 mg three times daily (this study) and
8 s (1.3 min) at 40 mg three times daily (previous trial) (15).
Both in the current study and in previous trials, fasudil
as well tolerated at the doses tested. No deaths occurred
uring these studies, and few serious treatment-related
dverse events were observed. Transient headache was the
ost frequent adverse event in both the fasudil and placebo
roups (15); however, skin and vascular disorders seemed to
iffer most between the groups. The contribution of fasudil-
ediated vasodilation to these adverse events should be
xplored. However, no clinically important changes in
aboratory results were found, and no adverse effects on
eart rate, blood pressure, or ECG were reported.
Taken together, these data suggest that the optimum oral
ose of fasudil for patients with stable angina may be 80
g three times daily. No plateau in the dose-response
elationship with regard to an increase in exercise time or
hanges in ST-segment depression was observed for fasudil
oses up to 80 mg three times daily. Furthermore, the
ignificant decrease in myocardial ischemia found at peak
fter administration of fasudil may be better maintained
etween doses with a higher starting dose. Suboptimal
osing may also explain the lack of a significant effect on
xercise time and the lack of reduction in anginal frequency
nd nitroglycerin use. Because fasudil is well-tolerated by
atients at the doses tested to date, evaluation of higher
osing seems to be feasible and warranted.
Because study duration and dose are linked in this study,
ncreased study duration may influence the results, particu-
arly with respect to the frequency of anginal episodes and
eekly nitroglycerin use. It is encouraging that quality of life
mprovements were observed within the study period. A
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Fasudil in Patients With Stable Angina November 15, 2005:1803–11uture study should examine the effects of higher doses of
asudil for a longer period of time.
Because of its unique mechanism of action, fasudil may
e a useful adjunctive therapy to standard therapies for
table angina. By inhibiting Rho kinase, which mediates the
asoconstriction stimulated by a wide variety of agonists,
asudil may inhibit the effects of vasoconstrictors that are
able 3. Body Systems With Treatment-Emergent Adverse Even
ody System
Placebo (n  43)
n (%)
Specific Events, No. of
kin and subcutaneous disorders 2 (5)
Diaphoresis, 1
Erythematous rash, 1
ervous system disorders 8 (20)
Burning sensation (hand
Dizziness, 1
Headache, 3
Lightheadedness, 3
ascular disorders 3 (7)
Ecchymosis, 1
Face flushing, 1
Flushing, 1
nfections and infestations 6 (14)
Bronchitis, 1
Fungal dermatitis, 1
Sinus infection, 1
Sinusitis, 1
Stomach virus, 1
Upper respiratory infecti
ardiac disorders 6 (14)
Arrhythmia, bradycardia
PVCs, 1
Myocardial infarction, 1
Myocardial ischemia, PV
SVT, 1
Unstable angina, 1
Worsening angina, 1
VC  premature ventricular contractions; SVT  supraventricular tachycardia.
able 4. Changes in Vital Signs at Peak at the End of
readmill Exercise (Week 8, 80 mg Three Times Daily)*
Parameter
Placebo
(n  36)
Fasudil
(n  33)
eart rate (beats/min) 1.8  13.13 1.2  14.77
ystolic blood pressure (mm Hg) 5  20.23 0.1  19.46
iastolic blood pressure (mm Hg) 1.2  7.71 3.1  9.55
ouble product (systolic blood
pressure·heart rate or
mm Hg·beats/min) 263  3,569 253  3,727All differences between groups are non-significant. Values are mean  SD.naffected by current therapies. Although it is likely that the
ptimal dose of fasudil for treatment of stable angina has
ot yet been established, the current efficacy and safety
esults justify further investigation of its therapeutic prop-
rties.
cknowledgments
he authors thank Mary Beth DeYoung, PhD, and Nina
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PPENDIX
or the modified Balke protocol as well as a list of the
articipating investigators in the Fasudil Study Group,
lease see the online version of this article.
